Advanced search
Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 33, 2009 - Issue sup1
Submit an article Journal homepage
371
Views
15
CrossRef citations to date
0
Altmetric
PROCEEDINGS OF THE 1ST PAN-MIDDLE EASTERN CONFERENCE ON HAEMOGLOBINOPATHIES DAMASCUS (SYRIA), 1–2 MAY, 2009 GUEST EDITORS: MICHAEL ANGASTINIOTIS AND ANDROULLA ELEFTHERIOUThe Eighth Section: Molecular Therapeutics

Fetal Globin Induction in β-thalassemia

Amal El-Beshlawy Pediatric Hematology Department, Cairo University Hospital, Cairo, EgyptCorrespondence[email protected]
,
Mona Hamdy Pediatric Hematology Department, Cairo University Hospital, Cairo, Egypt
&
Mona El Ghamrawy Pediatric Hematology Department, Cairo University Hospital, Cairo, Egypt
Pages S197-S203 | Published online: 13 Dec 2009

REFERENCES

  • Weatherall DJ, Clegg JB. The thalassemia syndromes. In: Weatherall DJ, Clegg B, eds. The Thalassemia Syndromes. 4th ed. Oxford, UK: Blackwell Science; 2001:287–356.
  • Higgs DR, Thein SL, Woods WG. The physiology of the thalassemia. In: Weatherall DJ, Clegg B, eds. The Thalassemia Syndromes. 4th ed. Oxford, UK: Blackwell Science; 2001:265–284.
  • Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2:245–255.
  • Gallo E, Massero P, Miniero R, David D, Tarella C. The importance of the genetic picture in globin synthesis in determining the clinical and hematological features of thalassemia intermedia. British Journal of Hematology. 1979;41:211–221.
  • Perrine SP. Fetal globin induction – can it cure beta thalassemia: Hematology. American Society of Hematology Education Program Book. 2005; 38–44.
  • Ikuta T, Kan YW, Swerdlow PS, Faller DV, Perrine SP. Alterations in protein-DNA interactions in the gamma-globin gene promoter in response to butyrate therapy. Blood. 1998;92(8):2924–2933.
  • De Simone J. The evolving role of DNA demethylating agents in the treatment of sickle cell disease and thalassemia. Semin Hematol. 2004;41(4 Suppl. 6):1–3.
  • Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol. 2005;1727(2):125–133.
  • Loukopoulos D, Voskaridou E, Stamoulakatou A, et al. Clinical trials with hydroxyurea and recombinant human erythropoietin. In Stamatoyannapoulos, G. and Nienhuis AW, ( eds), Hemoglobin Switching. New York: Alan R. Liss; 1995:365–372.
  • Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenyl butyrate therapy in homozygous beta thalassemia: a clinical trial. Blood. 1995;85(1):43–49.
  • Perrine SP, Yang YM, Piga A, et al. Butyrate + EPO in beta thalassemia intermedia: interim findings of a phase II trial [abstract]. Blood. 2002;100:47a.
  • Cappellini MD, Graziadei G, Ciceri L. Oral isobutyramide therapy in patients with thalassemia intermedia: results of phase II open study. Blood Cells Mol Dis. 2000;26(1):105–111.
  • Mankidy R, Faller DV, Mabaera R. Short-chain fatty acids induce gamma-globin gene expression by displacement of a HDAC3-NcoR repressor complex. Blood. 2006;108(9):3179–3186.
  • Ley TJ, DeSimone J, Anagnou NP, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med. 1982;307(24):1469–1475.
  • Fathallah H, Atweh GF. DNA hypomethylation therapy for hemoglobin disorders molecular mechanisms and clinical applications. Blood Rev. 2006;20(4):227–234.
  • Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol. 2008;83(5):366–370.
  • Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia-a promising therapy. Ann Hematol. 2005;84(7):441–446.
  • El Beshlawy A, Abou EL-Ela M, El-Ghamrawy M, Abdel-Salam A, Gaafar T, Mostafa A. The clinical and hematological responses to hydroxyurea in children with thalassemia intermedia. [U11]TIF 11th International Conference on Thalassemia and Haemoglobinopathies, Singapore, October 8–11, 2008; ALT06: 99.
  • Taher A, Ismaeel H, Cappellini M. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006; (13):117–122.
  • Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380–385.
  • Lampronti I, Bianchi N, Boratti M, Fibach E, Prus E, Gambari R. Accumulation of gamma globulin mRNA in human erythroid cells treated with angelicin. Eur J Haematol. 2003;71:189–195.
  • Gamabari R. Novel trends for the discovery and characterization of modifiers of globin gene expression10th International Thalassemia Conference, Cairo, May 6–7 2009.
  • Bianchi N, Zuccato C, Borgatti M, Bergamini P, Gambari R. Fetal hemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of β-thalassemia and sickle-cell anemia. Evid Based Complement Alternat. 2009;6(2):141–151.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.